CTLT241220P60000
- 1.55
- 0.000.00%
Catalent Newsroom
CDMO Market Opportunities and Competitive Landscape Report 2024, With Profiles of Thermo Fisher Scientific, Merck, Lonza, Catalent and WuXi AppTec
How to adjust the new national medical insurance catalog? Here is the explanation.
1. The success rate is 76%, with an average decline of 63%. This year, the success rate and decline of negotiating/bidding pharmaceuticals are basically equivalent to previous years; 2. This year, the fund calculation will pay more attention to the impact on fund expenditure, while also enhancing the comprehensiveness and scientific nature of the calculation work; 3. This year's catalog adjustment places more emphasis on the actual clinical needs and patients' actual medication, highlighting support for true innovation.
Wolfe's Most Shorted 'Hit List' – FSLR, BE, WBA, SJM
European Equities Close Lower in Tuesday Trading
Market Chatter: Novo Holdings to Win EU Approval for $16.5 Billion Catalent Takeover
The EU may unconditionally approve novo-nordisk a/s's acquisition of catalent.
The European Commission may unconditionally approve novo-nordisk a/s's parent company, Novo Holdings, to acquire the usa contract pharmaceutical company catalent for 16.5 billion USD.
EU Antitrust Regulators Expected to Approve Novo Holdings' $16.5B Acquisition of Catalent Without Conditions
Catalent Stock Soars to 52-week High, Hits $61.32
Morgan Stanley Lists Hedge Funds' Largest Q3 Ownership Increases in Russell 1000 Stocks
US Manufacturing Index Rises To 43, Highest Since 2020
EU regulatory institutions are inquiring about Novo Nordisk's acquisition of catalent.
According to sources, on November 14, the European Union's antitrust regulatory agency has requested feedback from pharmaceutical industry competitors and customers on four business areas regarding Novo Holdings' plan to invest $16.5 billion in acquiring Catalent. Novo Holdings, the controlling shareholder of Danish pharmaceutical company Novo Nordisk A/S, has become the highest market cap company in Europe driven by the generous profits from the popular weight loss drug Wegovy. While survey results show that the European Commission is seeking market insights, it may allow competitors and customers to raise potential antitrust concerns.
EU Regulators See Info From Rivals, Customers in Catalent Sale to Novo Holdings - Reuters
EU Regulators Quiz Novo Nordisk, Catalent Rivals on $16.5 Billion Deal
Medical stocks collectively surged! Bullish news has arrived, the medical sector welcomes a catalyst.
The medical sector with lagging growth finally sees a catalyst! Analysis believes that for medical institutions, prepayment of medical insurance funds helps optimize and improve the daily operation cash flow and financial pressure of medical institutions, reducing the potential receivables and bad debt risks caused by unpaid medical insurance expenses. For medical insurance, it enhances the settlement efficiency and encourages the active diagnosis and treatment enthusiasm of medical institutions.
Barclays Maintains Catalent(CTLT.US) With Hold Rating, Maintains Target Price $63
Analysts Have Conflicting Sentiments on These Healthcare Companies: Catalent (CTLT), Moderna (MRNA) and HCA Healthcare (HCA)
Jefferies Maintains Catalent(CTLT.US) With Hold Rating, Maintains Target Price $63.5
Catalent's Biologics Underperformance and PCH Stability Lead to Hold Rating
Novo Nordisk CFO: Believe Catalent Deal Will Close by Yr-End Based on Regulator Interactions
Catalent | 10-Q: Q1 2025 Earnings Report